Boston Scientific has entered into a definitive agreement to acquire Baylis Medical for an initial payment of $ 1.75 billion, subject to final changes.

The acquisition will expand Boston Scientific's portfolio of electrophysiology and structural cardiac products to include radio frequency (RF) NRG and VersaCross Transseptal Platforms, as well as a range of guidewires, sheaths and dilators used to support left ventricular access.

It is doing well with ambitions to add to what it says about the growth of drug candidates from its artificial intelligence-based discovery platform, as well as to the breadth of functions the system serves, Exscientia plc said on January 7 that it will be a Long partner of Sanofi. SA will develop 15 new candidates for small molecules to designate oncology and immunology. Sanofi will pay Exscientia $ 100 million and up to $ 5.2 billion in total milestones, including tiered royalties, the company said.

A subsidiary of 3Sbio Inc., Sunshine Guojian Pharmaceutical Co. Ltd., licenses worldwide rights to its anti-PD-1 anticoding candidate, 609-A, Syncromune Inc. based in Florida stated in the agreement that the company is suitable. to "hundreds of millions of US dollars."

Stryker Corp. announced that it has signed a final merger agreement with Vocera Communications Inc. $ 2.97 billion in a cash transaction that is expected to close in the first quarter of this year. Vocera provides digital health and communications services that Stryker says are designed to help hospitals connect caregivers and the various medical devices that generate data, such as wearable devices, interconnected beds, outpatient equipment, badges and alarms.